As I said sometime back, azixa in brain cancer is the one prospect that could potentially turn things around and is the ONLY thing I see in their pipe worth watching out for.
But I place odds of a resounding success at 1 in 4.
And back on the NP1 topic - someone here posted an interview excerpt from Talley touting the great promise of NP1. His statements are utter nonsense and smack of the exact types of statements he made about ceplene, no difference whatsoever.
Its all a merry go round, folks, and the fuel for that ride is the short memories of investors.
No thanks, not my kind of wager to make, plus I am already right.
Well over a year ago I discussed NP1 at length and one of my predictions was that there would be no significant partnership. Simply because the patient population is small enough to earn it an orphan designation doesn't change that. Its a crowded field, lots of competition, lots of further advanced drugs and platforms that can easily address this need, not to mention generics.
This drug and its data have been around a long long time, if there was significant interest, it would have snapped up long ago.
Sure it may find a partner, but like ceplene, it wont be a game changer for this company. What's going on here is that this group of management goons milked and hyped ceplene for all they could, but eventually they had to pay the piper, and just as I predicted, the terms were about as minimal as possible.
This round of NP1 talk is them just moving onto the next pump, microcap biotechs are just a merry go 'round, nothing more, these guys aren't anymore guilty than a hundred others, they just aren't as good at it as others.